接受免疫检查点抑制剂治疗的癌症患者中乙型肝炎的功能性治愈
该研究回顾性纳入接受免疫检查点抑制剂(ICI)且HBsAg阳性的癌症患者(队列1 n=118,队列2 n=44作为验证),并设未接受ICI的HBV-HCC对照队列(队列3 n=85)。中位随访17.5个月,队列1有8例(6.8%)、队列2有4例(9.1%)实现HBsAg清除;基线HBsAg<100 IU/ml与HBsAg清除相关(HR 6.274,p=0.028),验证队列中该组12和24个月HBsAg丢失累积发生率分别为13.0%和38.4%,显著高于对照组(p=0.0267)。结论认为ICI可能加速基线HBsAg<100 IU/ml癌症患者的HBsAg清除。
要点
- 接受ICI的癌症患者中,队列1有6.8%、队列2有9.1%实现HBsAg清除。
- 基线HBsAg<100 IU/ml与HBsAg清除相关,HR为6.274(p=0.028)。
- 验证队列基线HBsAg<100 IU/ml者12和24个月HBsAg丢失累积发生率为13.0%和38.4%,高于对照组(p=0.0267)。
核心结论
- ICI可能加速基线HBsAg<100 IU/ml的癌症患者的HBsAg血清清除。
- 该发现为未来评估ICI诱导CHB功能性治愈能力的试验设计提供了重要信息。
研究设计与样本
- 回顾性纳入2016至2020年连续癌症患者(队列1,n=118)和2020至2022年肝细胞癌患者(队列2,n=44,作为验证),均为接受ICI且HBsAg阳性。
- 另设未接受ICI的HBV-HCC队列(队列3,n=85)作为对照组。
- 分析与HBsAg丢失或HBsAg下降>1 log相关的因素。
主要发现
- 中位随访17.5个月,队列1有8例(6.8%)、队列2有4例(9.1%)实现HBsAg血清清除。
- 队列1另有4例、队列2另有1例出现HBsAg下降>1 log。
- 多因素分析显示基线HBsAg<100 IU/ml与HBsAg血清清除相关(HR 6.274,p=0.028)。
- 验证队列中基线HBsAg<100 IU/ml者12和24个月HBsAg丢失累积发生率分别为13.0%和38.4%,显著高于对照组(p=0.0267)。
- 队列3在24个月内无病例实现HBsAg丢失;17例实现HBsAg丢失或下降>1 log的病例中16例(94.1%)接受了核苷(酸)类似物治疗,中位至HBsAg丢失或下降时间为16.5个月(范围9.6至27.5)。
关键数值与推荐
- 基线HBsAg<100 IU/ml与HBsAg血清清除相关,HR为6.274(p=0.028)。
- 验证队列基线HBsAg<100 IU/ml者12个月HBsAg丢失累积发生率为13.0%,24个月为38.4%,显著高于对照组(p=0.0267)。
- 17例实现HBsAg丢失或下降>1 log的病例中,16例(94.1%)接受了核苷(酸)类似物治疗。
- 至HBsAg丢失或HBsAg下降的中位时间为16.5个月(范围9.6至27.5)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Immune checkpoint inhibitors (ICIs) can restore exhausted T-cell immunity not only for cancer treatment but also potentially to cure chronic hepatitis B (CHB). Thus, we aimed to determine the previously unclear impact of ICIs on hepatitis B surface antigen (HBsAg) seroclearance in patients with cancer. METHODS: Consecutive patients with cancer from 2016 to 2020 (cohort 1, n = 118), and hepatocellular carcinoma from 2020 to 2022 (cohort 2, n = 44, as validation) receiving ICIs and positive for HBsAg were retrospectively recruited. An additional HBV-HCC cohort (cohort 3, n = 85) not receiving ICIs served as a control group. Factors associated with HBsAg loss or a HBsAg decline >1 log were analyzed. RESULTS: With median follow-up of 17.5 months, 8 (6.8%) patients in cohort 1 and 4 (9.1%) in cohort 2 achieved HBsAg seroclearance, and an additional four in cohort 1 and one in cohort 2 had a HBsAg decline >1 log. In multivariate analysis, HBsAg <100 IU/ml was associated with HBsAg seroclearance (hazard ratio 6.274, p = 0.028). In the validation cohort, the cumulative incidences of HBsAg loss at months 12 and 24 were 13.0% and 38.4%, respectively, for baseline HBsAg <100 IU/ml, which were significantly higher than those in the control group (p = 0.0267). No case in cohort 3 achieved HBsAg loss within 24 months. Of the 17 cases who achieved HBsAg loss or a decline >1 log, 16 (94.1%) received nucleos(t)ide analogue treatment. The median time to HBsAg loss or HBsAg decline was 16.5 (range 9.6 to 27.5) months. CONCLUSIONS: ICIs may accelerate HBsAg seroclearance in patients with cancer and baseline HBsAg <100 IU/ml. This finding provides important information for the design of future trials evaluating the ability of ICIs to induce functional cure in patients with CHB. IMPACT AND IMPLICATIONS: Immune checkpoint inhibitors (ICIs) can restore exhausted T-cell immunity not only for cancer treatment but also potentially to cure chronic hepatitis B. Functional cure of hepatitis B was observed in patients with cancer or HCC undergoing ICI treatment, and the cumulative incidence of HBsAg loss was higher compared with controls without ICIs. ICIs may accelerate the HBsAg loss in patients with baseline HBsAg levels <100 IU/ml. This finding provides important information for the design of future ICI trials evaluating the ability of ICIs to induce functional cure in patients with CHB.
引用
- Mon HC, Lee PC, Hung YP, et al. Functional cure of hepatitis B in patients with cancer undergoing immune checkpoint inhibitor therapy. J Hepatol. 2024. PMID: 39084471. doi:10.1016/j.jhep.2024.07.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。